Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
暂无分享,去创建一个
I. Reis | R. Ramasamy | T. Masterson | I. Zucker | R. Saltzman | M. Molina | B. Ledesma | E. Ibrahim | Sunwoo Han
[1] J. Mills,et al. Analysis of Direct-to-Consumer Marketing of Platelet-Rich Plasma for Erectile Dysfunction in the US , 2022, JAMA Network Open.
[2] B. Nuhoğlu,et al. Early Clinical Results of the Tolerability, Safety, and Efficacy of Autologous Platelet-Rich Plasma Administration in Erectile Dysfunction , 2021, Sexual medicine.
[3] Meghan M. Miller,et al. Cellular Components and Growth Factor Content of Platelet-Rich Plasma With a Customizable Commercial System , 2019, The American journal of sports medicine.
[4] M. Faraday,et al. Erectile Dysfunction: AUA Guideline , 2018, The Journal of urology.
[5] A. Pearlman,et al. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions , 2017, Investigative and clinical urology.
[6] A. Burnett,et al. Neuroprotective and Nerve Regenerative Approaches for Treatment of Erectile Dysfunction after Cavernous Nerve Injury , 2017, International journal of molecular sciences.
[7] M. Ćirić,et al. Platelet Rich Plasma: a short overview of certain bioactive components , 2016, Open medicine.
[8] T. Kim,et al. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients , 2013, International Journal of Impotence Research.
[9] Q. Guo,et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. , 2013, Osteoarthritis and cartilage.
[10] H. Chiang,et al. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. , 2012, The journal of sexual medicine.
[11] J. Marôco,et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. , 2012, The journal of sexual medicine.
[12] A. Araujo,et al. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. , 2011, European urology.
[13] F. Montorsi,et al. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. , 2011, The journal of sexual medicine.
[14] Xin-min Zheng,et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. , 2009, Asian journal of andrology.
[15] C. Derby,et al. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study , 2000, International Journal of Impotence Research.